Navigation Links
Limit to nanotechnology mass-production?
Date:4/20/2011

A leading nanotechnology scientist has raised questions over a billion dollar industry by boldly claiming that there is a limit to how small nanotechnology materials can be mass produced.

In a paper published today, Thursday, 21 April, in IOP Publishing's journal Nanotechnology, Professor Mike Kelly, Centre for Advanced Photonics and Electronics, University of Cambridge, stated that you cannot mass produce structures with a diameter of three nanometres or less using a top-down approach.

This statement raises a major question concerning the billions of dollars that are poured into nanotechnology each year in the hope that the latest technology developed in the lab can make the transition to a manufactured product on the market.

Nanotechnology is built on the ability to control and manipulate matter at the atomic and molecular level and has far reaching applications including the delivery of drugs into the body, increasing the efficiency of solar panels and improving methods of food packaging.

The overall goal when entering nanotechnologies into the market is low-cost, high-volume manufacturability, but at the same time, the materials' properties must be highly reproducible within a pre-specified limit, which Kelly states cannot happen below the 3nm limit when trying to make arrays.

The top-down approach to manufacturing, which Kelly states is limited, uses external tools to cut and shape large materials to contain many smaller features. Its alternative, the bottom-up approach, involves piecing together small units, usually molecules, to construct whole materials much like a jigsaw puzzle however this process is too unpredictable for defect free mass production of arrays.

Kelly used statistical evaluation of vertical nanopillars - that have been suggested for uses in sensors and displays - as an example to demonstrate his theory. He states that the proof comes in two stages. The first is due to the fact that when materials are mass produced on such a small scale there will be a lot of variation in the size of different components.

As a result of this variation, the properties of the material will vary to an extent where the material cannot function to full capacity within an array.

Professor Kelly says, "If I am wrong, and a counterexample to my theorem is provided, many scientists would be more secure in their continued working, and that is good for science.

"If more work is devoted to the hard problem of understanding just what can be manufactured and how, at the expense of more studies of things that cannot be manufactured under the conditions of the present theorem, then that too is good for science and for technology."


'/>"/>

Contact: Joe Winters
joseph.winters@iop.org
44-207-470-4815
Institute of Physics
Source:Eurekalert

Related biology technology :

1. World TB Day Donation Campaign Increases Access to Improved TB Tests in Resource-Limited Settings
2. Healthzone Limited Engages The Trout Group for Investor Relations Services
3. Earthshaking possibilities may limit underground storage of carbon dioxide
4. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
5. New President and CEO appointed at Ocean Nutrition Canada Limited
6. O2h Continues to Support Senexis to Support Patent Filing Senexis Limited
7. The Independent Committee of the Board of Directors of Tongjitang Appoints Morgan Stanley Asia Limited as Its Financial Advisor
8. Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited
9. DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services
10. Bunge Limited to Expand Sugar and Bioenergy Business in Brazil
11. Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):